International access
Cancer treatment in China
High case volume and broad clinical trial participation, especially in cellular therapy.
Orientation information, not an access guarantee
Facilities
Public-reference profiles
This list does not state partnership, quality, schedule, price, or international patient acceptance.
- Not verified
Foshan Fosun Chancheng Hospital
Foshan
- Not verified
Sun Yat-sen University Cancer Center
Guangzhou
- Not verified
Fudan University Shanghai Cancer Center
Shanghai
- Not verified
Peking Union Medical College Hospital
Beijing
Public registry
Recorded clinical trials
Available clinical trial counts are calculated from public registries and may change at any time. Counts shown on the page follow the most recent registry data imported.
NCT03460977Phase 1Combination regimen
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
United States, Bulgaria, China +584 registry sites
Why this appears: Appears because it is recorded for Lung Cancer.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT03460977Not verified
NCT04728893Phase 2Combination regimen
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
United States, Argentina, Australia +19121 registry sites
Why this appears: Appears because it is recorded for Lymphoma.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT04728893Not verified
NCT05139017Phase 2 / Phase 3Immunotherapy
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Lymphoma | Immunotherapy, Chemotherapy
United States, Argentina, Australia +23135 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05139017Not verified
NCT06170788Phase 3Immunotherapy
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Lung Cancer | biomarker: PD-L1 | Immunotherapy, Perawatan suportif dan paliatif
United States, Argentina, Australia +23220 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06170788Not verified
What needs confirmation
- • Visa, stay permit, and entry requirements for medical care must be checked through official government and embassy channels. TanyaKanker does not guarantee acceptance.
- • Service availability, written estimate, inclusions and exclusions.
- • Follow-up plan after returning to Indonesia.
Ask about access in China
Organise the case and questions without promises of acceptance, price, or treatment outcome.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.